EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Dofetilide for the treatment of premature ventricular complexes and ventricular tachycardia in patients with structural heart disease

Amrish Deshmukh iD, Miki Yokokawa, Daniel McBride, Jamie Simpson, Andrew Chou iD, Michael Ghannam iD, Jackson J Liang iD, Mohammed Saeed, Ryan Cunnane, Hamid Ghanbari, Rakesh Latchamsetty, Thomas Crawford iD und 6 weitere

Journal of Cardiovascular Electrophysiology · 2024

DOI: 10.1111/jce.16452 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Cardiovascular Electrophysiology, 2024. Verfasst von Amrish Deshmukh und 17 weiteren Autor:innen. Beteiligte Einrichtung: Division of Cardiovascular Medicine, Cardiac Arrhythmia Service, University of Michigan, Ann Arbor, Michigan, USA. Hauptthemen laut MEDLINE: Phenethylamines, Anti-Arrhythmia Agents, Ventricular Premature Complexes, Tachycardia, Ventricular. Die Arbeit nennt 18 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: None.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Dofetilide is a class III antiarrhythmic agent approved for the treatment of atrial fibrillation and atrial flutter. Given the efficacy of other class III agents, it has been used off‐label for the treatment of premature ventricular complexes (PVCs) and ventricular tachycardias (VTs).

Objective

The purpose of this study was to determine the efficacy and safety of dofetilide for ventricular arrythmias (VAs).

Methods

In this retrospective cohort study, 81 patients (59 men; age = 60 ± 14 years; LVEF = 0.34 ± 0.16) were admitted for dofetilide initiation to treat PVCs (29), VTs (42) or both (10). A ≥ 80% decrease in PVC burden was defined as a satisfactory response. An ICD was present in 72 patients (89%). Another antiarrhythmic was previously used in 50 patients (62%). Prior catheter ablation had been performed in 33 patients (41%).

Results

During intitiation, dofetilide was discontinued in 12 patients (15%) due to QT prolongation (8) and inefficacy to suppress VAs (4). Among the 32 patients with PVCs who successfully started dofetilide, the mean PVC burden decreased from 20 ± 10% to 8 ± 8% at a median follow‐up of 2.6 months ( p < .001). PVC burden was reduced by ≥80% in only 11/32 patients (34%). During 7 ± 1 years of follow‐up, 41/69 patients (59%) continued to have VAs and received appropriate ICD therapies for monomorphic VTs (35) and polymorphic VT/VF (6) at a median of 8.0 (IQR 2.6–33.2) months. Dofetilide had to be discontinued in 50/69 patients (72%) due to inefficacy or intolerance. The composite outcome of VT/VF recurrence, heart transplantation, or death occurred in 6/12 patients (50%) without dofetilide and 49/69 patients (71%) with dofetilide. The event free survival was similar between patients treated with and without dofetilide (log‐rank p = .55).

Conclusions

Treatment with dofetilide was associated with a decrease in PVCs, however clinically significant suppression occurred in a minority of patients. Dofetilide failed to suppress the occurrence of VTs in a majority of patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

PhenethylaminesAnti-Arrhythmia AgentsVentricular Premature ComplexesTachycardia, VentricularSulfonamidesHumansMaleFemaleMiddle AgedRetrospective StudiesAgedTreatment OutcomeTime FactorsHeart RateAction PotentialsRisk FactorsRecurrence

Stichwörter der Autor:innen

antiarrhythmic drugdofetilidepremature ventricular complexventricular Tachycardiaventricular arrhythmia

Substanzen

PhenethylaminesdofetilideAnti-Arrhythmia AgentsSulfonamides

Autor:innen und Institutionen

  • Division of Cardiovascular Medicine, Cardiac Arrhythmia Service, University of Michigan, Ann Arbor, Michigan, USA.
  • Henry Ford Heart and Vascular Institute, Henry Ford Hospital, Detroit, Michigan, USA.

ORCID-Profile: Amrish Deshmukh, Andrew Chou, Michael Ghannam, Jackson J Liang, Thomas Crawford, Frank Pelosi, Aman Chugh, Frank Bogun, Hakan Oral

Förderung

  • None

Zitieren

APA

Deshmukh, A., Yokokawa, M., McBride, D., Simpson, J., Chou, A., Ghannam, M., Liang, J. J., Saeed, M., Cunnane, R., Ghanbari, H., Latchamsetty, R., Crawford, T., Jongnarangsin, K., Pelosi, F., Chugh, A., Morady, F., Bogun, F., & Oral, H. (2024). Dofetilide for the treatment of premature ventricular complexes and ventricular tachycardia in patients with structural heart disease. Journal of Cardiovascular Electrophysiology. https://doi.org/10.1111/jce.16452

Vancouver

Deshmukh A, Yokokawa M, McBride D, Simpson J, Chou A, Ghannam M, et al. Dofetilide for the treatment of premature ventricular complexes and ventricular tachycardia in patients with structural heart disease. Journal of Cardiovascular Electrophysiology. 2024. doi:10.1111/jce.16452

BibTeX
@article{Deshmukh2024,
  author = {Deshmukh, Amrish and Yokokawa, Miki and McBride, Daniel and Simpson, Jamie and Chou, Andrew and Ghannam, Michael and Liang, Jackson J and Saeed, Mohammed and Cunnane, Ryan and Ghanbari, Hamid and Latchamsetty, Rakesh and Crawford, Thomas and Jongnarangsin, Krit and Pelosi, Frank and Chugh, Aman and Morady, Fred and Bogun, Frank and Oral, Hakan},
  title = {Dofetilide for the treatment of premature ventricular complexes and ventricular tachycardia in patients with structural heart disease},
  journal = {Journal of Cardiovascular Electrophysiology},
  year = {2024},
  doi = {10.1111/jce.16452}
}
Kostenlos starten →